RxDoctor Payments Data

Joseph Ferrara, MD

Neurology · Columbia, SCNPI 1942450002

Payments from drug & device makers

What this record shows

8 manufacturers reported payments, led by AstraZeneca at 33.6% of the total. 2025 is the largest year on record at $132, 8.1 times the $16 reported in 2023. That places this record below the midpoint for neurology clinicians in SC, where the typical reported total is $752.

$223in general payments, 2019–2025

Across 10 payments — averaging $22.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$75
  • AbbVie$43
  • Neurelis, Inc.$22
  • Amgen$20
  • EMD Serono, Inc.$18
  • Cala Health, Inc.$16
  • plus $29 from 2 others
$98,980in research payments, 2019–2025

Across 12 payments — averaging $8248.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Mallinckrodt Hospital Products Inc.$57K
  • Mallinckrodt Enterprises LLC$25K
  • H. Lundbeck A S$17K

What the payments were for

  • Food & beverage$13360%
  • Education$9040%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$223 in reported general payments places this provider in the 30th percentile of 270 neurology providers in South Carolina.

See all neurology providers in South Carolina

Medicare billing

Part B allowed, 2024
$166,647
Medicare patients
519
Services billed
10,410

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
InbrijaLevodopa20$86,305
NuplazidPimavanserin Tartrate18$83,602
RytaryCarbidopa/Levodopa23$54,095
AptiomEslicarbazepine Acetate11$27,236
QuliptaAtogepant23$24,571
XcopriCenobamate22$23,452
Carbidopa-LevodopaCarbidopa/Levodopa573$20,993
BriviactBrivaracetam11$15,228
Aimovig AutoinjectorErenumab-Aooe17$12,477
MyrbetriqMirabegron15$11,409
Primidone214$9,531
Levetiracetam266$7,863
Entacapone42$7,703
Carbamazepine ErCarbamazepine49$7,150
Lacosamide53$6,444

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta$43$24,57123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 270 neurology providers in South Carolina.

Other neurology in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →